The flagship Advancing Precision Medicine Annual Conference is happening November 1- 2 in Philadelphia, PA and Haystack will be there! This inaugural event provides an excellent opportunity to delve into the world of precision oncology, where innovative breakthroughs are transforming cancer diagnosis and treatment.
Visit our booth to learn about Haystack MRD™, our next-generation minimal residual disease (MRD) test that delivers exceptional sensitivity.
Attend the talk
Join us for a presentation to learn more about how Haystack MRD is elevating confidence in cancer management.
Detecting the unseen: How Haystack MRD™ can help guide treatment decisions with more confidence
Presented by:
Thomas Slavin, MD, MBA
Chief Clinical Officer of Molecular Oncology and Medical Director of Haystack Oncology at Quest Diagnostics
Date: Saturday, November 2
Time: 1:10 – 1:40 PM
About Haystack MRD
Haystack MRD is a tumor-informed, next-generation minimal residual disease (MRD) test that detects ultralow levels of circulating tumor DNA (ctDNA) to uncover residual disease after definitive surgery. Haystack Oncology represents the culmination of over 20 years of collaboration to advance technical and clinical development in liquid biopsy technologies by cancer genomics pioneers at Johns Hopkins School of Medicine. Our purpose-built, high-precision science delivers novel insights that can help inform treatment decision-making, personalizing the guidance you give patients and empowering you to improve their lives with more certainty than ever before.
Haystack MRD is backed by the power of Quest Diagnostics for seamless access along the cancer care continuum.
